INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease



Status:Recruiting
Conditions:Cancer, Blood Cancer, Hematology, Leukemia
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:1 - 21
Updated:5/5/2014
Start Date:September 2010

Use our guide to learn which trials are right for you!

A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms

RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth.

PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424
in treating young patients with relapsed or refractory solid tumor, leukemia, or
myeloproliferative disease.

OBJECTIVES:

Primary

- To estimate the maximum-tolerated dose and/or recommended phase II dose of oral JAK
inhibitor INCB18424 administered continuously, twice daily to pediatric patients with
relapsed or refractory solid tumors.

- To define and describe the toxicities of this treatment administered on this schedule
in pediatric patients with relapsed or refractory solid tumors, leukemias, or
myeloproliferative neoplasms (MPNs).

- To characterize the pharmacokinetics of this treatment in pediatric patients with
relapsed or refractory solid tumors, leukemias, or MPNs.

Secondary

- To preliminarily define the antitumor activity of this treatment within the confines of
a phase I study.

- To assess the biologic activity of oral JAK inhibitor INCB18424 upon JAK-STAT signaling
in pediatric patients with relapsed or refractory solid tumors, leukemias, or MPNs.

- To assess the cytotoxicity and biologic activity of oral JAK inhibitor INCB18424 upon
phosphosignaling and mutation burden in pediatric patients whose leukemias or MPNs have
known CRLF2 and/or JAK mutations.

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive oral JAK inhibitor INCB18424 twice daily on days 1-28. Courses repeat every
28 days in the absence of disease progression or unacceptable toxicity.

Patients with relapsed or refractory leukemia may receive intrathecal chemotherapy in course
2 and subsequent courses at the discretion of the treating physician.

Plasma, bone marrow, and blood samples may be collected at baseline, during course 1, and
before subsequent courses for pharmacokinetic analysis and correlative biology studies.

After completion of study treatment, patients are followed up for 30 days.

DISEASE CHARACTERISTICS:

- Histologically confirmed diagnosis of one of the following:

- Relapsed or refractory extracranial solid tumor

- Relapsed or refractory leukemia

- At least 25% blasts in the bone marrow (M3) with the exception of patients
with acute myeloid leukemia (AML), who must have > 20% blasts in the bone
marrow

- Relapsed or refractory myeloproliferative neoplasm (MPN)

- At original diagnosis or relapse

- Current diagnostic criteria for MPNs include polycythemia vera, essential
thrombocythemia, juvenile myelomonocytic leukemia, myelofibrosis, and
atypical chronic myeloid leukemia

- Relapsed or refractory leukemia or MPN that have confirmed JAK mutations and/or
positive TSLPR surface staining

- Testing for JAK mutations and/or confirmed positive flow cytometry surface
staining for the thymic stromal lymphopoietin receptor (TSLPR; encoded by
CRLF2); eligibility for part C will be contingent upon patients
demonstrating overexpression of CRLF2 by flow cytometric methods measured
at either JHU or U. Washington flow laboratories (therefore, pre-enrollment
samples need to be sent to one of these laboratories after discussion with
Dr. Loh) or if the patient has a CLIA lab documented alteration in JAK1 or
JAK2, SH2B3, IL7RA, or another gene that would predict sensitivity to JAK
inhibition.

- Measurable or evaluable disease (for patients with solid tumors)

- Current disease state is one for which there is no known curative therapy or therapy
proven to prolong survival with an acceptable quality of life

- No known active CNS involvement (radiographic or cytologic)

PATIENT CHARACTERISTICS:

- Karnofsky performance status (PS) 50-100% (for patients > 16 years old) or Lansky PS
50-100% (for patients ≤ 16 years old)

- Patients who are unable to walk because of paralysis, but who can actively sit
up in a wheelchair, will be considered ambulatory for the purpose of assessing
the performance status

- Patients with solid tumors* must meet the following criteria:

- Peripheral ANC ≥ 1,000/mm^3

- Platelet count ≥ 100,000/mm^3 (transfusion-independent, defined as > 7 days
since prior platelet transfusions)

- Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)

- Not refractory to to red cell or platelet transfusion

- ALT ≤ 110 U/L NOTE: *Patients with solid tumors and known bone marrow metastatic
disease are eligible for study, but not evaluable for hematologic toxicity.
These patients must not be known to be refractory to RBC or platelet
transfusions.

- Patients with leukemia or MPNs must meet the following criteria:

- Platelet count ≥ 20,000/mm^3 (may receive platelet infusions)

- Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)

- ALT ≤ 225 U/L

- Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on
age/gender as follows:

- ≤ 0.6 mg/dL (for patients 1 to < 2 years old)

- ≤ 0.8 mg/dL (for patients 2 to < 6 years old)

- ≤ 1 mg/dL (for patients 6 to < 10 years old)

- ≤ 1.2 mg/dL (for patients 10 to < 13 years old)

- ≤ 1.4 mg/dL (for female patients ≥ 13 years old)

- ≤ 1.5 mg/dL (for male patients 13 to < 16 years old)

- ≤ 1.7 mg/dL (for male patients ≥ 16 years old)

- Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 times upper limit of normal for
age

- Serum albumin ≥ 2 g/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Able to swallow crushed or whole tablets

- Nasogastric or G tube administration is not allowed

- Body surface area ≥ 0.65 m^2 (for patients at dose level -1, 1, and 2)

- No uncontrolled infection, including patients with known active HIV or chronic
hepatitis

- No patients who, in the opinion of the investigator, may not be able to comply with
the safety monitoring requirements of the study

PRIOR CONCURRENT THERAPY:

- Fully recovered from the acute toxic effects of all prior anticancer therapy

- At least 2 weeks since prior local palliative radiotherapy (small port)

- At least 6 months since prior total-body irradiation (TBI), craniospinal
radiotherapy, or radiotherapy to ≥ 50% of the pelvis (for patients with solid tumors)

- At least 3 months since prior TBI, craniospinal radiotherapy, or radiotherapy to ≥
50% of the pelvis (for patients with leukemia)

- At least 3 months since prior stem cell transplantation or rescue without TBI and no
evidence of active graft-vs-host disease

- At least 6 weeks since other substantial bone marrow radiation

- At least 3 weeks since prior myelosuppressive therapy (6 weeks for nitrosourea) (for
patients with solid tumors)

- At least 2 weeks since prior cytoxic chemotherapy (for patients with leukemia or
MPNs)

- Hydroxyurea may be initiated and continued for up to 24 hours before the start
of study treatment

- Intrathecal cytarabine (Ara-C) is not myelosuppressive chemotherapy

- Patients with leukemia are permitted to receive intrathecal chemotherapy,
including methotrexate or cytarabine, only if this is given at the time of
diagnostic lumbar puncture at least 24 hours prior to the start of INCB018424

- At least 2 weeks since prior long-acting hematopoietic growth factor (e.g., Neulasta)
or 1 week for a short-acting growth factor

- For agents that have known adverse events occurring beyond 1 week, this period
must be extended beyond the time during which adverse events are known to occur
(as discussed with the study chair)

- At least 1 week since prior therapy with a biologic (antineoplastic) agent

- For agents that have known adverse events occurring beyond 1 week, this period
must be extended beyond the time during which adverse events are known to occur
(as discussed with the study chair)

- At least 3 half-lives of antibody since prior monoclonal antibody

- No other concurrent investigational drugs

- No other concurrent anticancer agents, including chemotherapy, radiotherapy,
immunotherapy, or biologic therapy

- No concurrent systemic steroids (i.e., prednisone > 10 mg)

- No concurrent aspirin > 150 mg/day

- No concurrent medications for myelofibrosis (e.g., hydroxyurea, interferon,
thalidomide, busulfan, lenalidomide, or anagrelide)

- No concurrent cyclosporine, tacrolimus, or other agents to prevent graft-vs-host
disease after bone marrow transplant or organ rejection after transplant
We found this trial at
24
sites
705 Riley Hospital Drive
Indianapolis, Indiana 46202
317.944.2060
Riley's Children Cancer Center at Riley Hospital for Children The Riley Hospital for Children Cancer...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
734-936-4000
C.S. Mott Children's Hospital at University of Michigan Medical Center Behind the doors of C.S....
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1405 Clifton Road Northeast
Atlanta, Georgia 30322
(404) 785-6000
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Baltimore, Maryland 21231
410-955-6190
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
1802 6th Avenue South
Birmingham, Alabama 35294
(205) 934-4011
UAB Comprehensive Cancer Center One of the nation’s leading cancer research and treatment centers, the...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
(617) 632-3000
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Founded in 1997, Dana-Farber/Harvard Cancer Center (DF/HCC) was...
?
mi
from
Boston, MA
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas From its...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
425 E River Pkwy # 754
Minneapolis, Minnesota 55455
612-624-2620
Masonic Cancer Center at University of Minnesota The Masonic Cancer Center was founded in 1991....
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
701 West 168th Street
New York, New York 10032
(212) 851-4680
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center The Herbert Irving Comprehensive Cancer...
?
mi
from
New York, NY
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
3181 SW Sam Jackson Park Rd
Portland, Oregon 97239
(503) 494-5058
Knight Cancer Institute at Oregon Health and Science University Cancer takes many forms. Although cancer...
?
mi
from
Portland, OR
Click here to add this to my saved trials
1600 Divisadero Street
San Francisco, California 94115
888.689.8273
UCSF Helen Diller Family Comprehensive Cancer Center UCSF’s long tradition of excellence in cancer research...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
4800 Sand Point Way Northeast
Seattle, Washington 98105
(206) 987-2000
Children's Hospital and Regional Medical Center - Seattle Seattle Children
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
2515 N Clark St
Chicago, Illinois 60614
(312) 227-6060
Children's Memorial Hospital, Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
One Baylor Plaza
Houston, Texas 77030
(713) 798-4951
Baylor University Medical Center - Houston Baylor University Medical Center in Dallas began in 1903...
?
mi
from
Houston, TX
Click here to add this to my saved trials
9000 W Wisconsin Ave
Milwaukee, Wisconsin 53226
(414) 266-2000
Midwest Children's Cancer Center at Children's Hospital of Wisconsin We are the region's only independent...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
?
mi
from
St. Louis, MO
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials